GlassScriptPhysician profile
Sarah C Hayes
NPI 1811408016
$58,648.14
in general payments reported to CMS, 2019-2025
35 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,369 · 2022: $10K · 2023: $28K · 2024: $6,447 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $8,309 · Travel and Lodging: $3,919 · Consulting Fee: $3,375 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,250.00 |
| Food and Beverage | $8,308.51 |
| Travel and Lodging | $3,919.26 |
| Consulting Fee | $3,375.00 |
| Education | $237.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $44,070.00 | 2021-2025 | Aklief, Epsolay, Oracea |
| Arcutis Biotherapeutics, INC. | $5,501.45 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,193.70 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,121.43 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $949.72 | 2021-2025 | |
| Janssen Biotech, INC. | $820.54 | 2022-2025 | Tremfya, Erleada, Akeega |
| Sun Pharmaceutical Industries INC. | $703.27 | 2021-2025 | Ilumya |
| Ucb, INC. | $495.13 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $407.13 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $396.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $395.34 | 2022-2025 | Sotyktu |
| Incyte Corporation | $338.93 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $277.66 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $264.19 | 2021-2025 | Cabtreo, Arazlo |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $232.64 | 2022-2025 | Adbry, Anzupgo |
| Organon LLC | $221.42 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $179.62 | 2023-2025 | Nuzyra |
| Amgen INC. | $131.10 | 2022-2025 | Otezla |
| Vyne Pharmaceuticals INC. | $125.02 | 2021 | |
| Janssen Scientific Affairs, LLC | $117.82 | 2022 | |
| Genzyme Corporation | $105.16 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $97.29 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $58.52 | 2023-2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $28.04 | 2022-2023 | Valchlor |
| Convatec INC. | $23.44 | 2025 | |
| Organogenesis INC. | $21.15 | 2023 | Puraply |
| Dendreon Pharmaceuticals LLC | $17.64 | 2023 | Provenge |
| Boston Scientific Corporation | $16.90 | 2024 | Rezum Generator |
| Journey Medical Corporation | $16.32 | 2022 | |
| Kyowa Kirin, INC. | $16.00 | 2024 | Poteligeo |
| Dermira, INC. | $15.12 | 2021 | |
| Merck Sharp & Dohme LLC | $13.67 | 2023 | Keytruda |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Nabriva Therapeutics, Plc | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.